MANNKIND CORP Foreign Currency Transaction Gain (Loss), Realized
MANNKIND CORP (MNKD) reported Foreign Currency Transaction Gain (Loss), Realized of $486.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ForeignCurrencyTransactionGainLossRealized · last filed 2026-08-05
- MANNKIND CORP foreign currency transaction gain (loss), realized for the quarter ending 2026-06-30 was $486.00K.
- MANNKIND CORP foreign currency transaction gain (loss), realized for the quarter ending 2026-03-31 was $1.32M.
- MANNKIND CORP foreign currency transaction gain (loss), realized for the quarter ending 2025-12-31 was $3.00K, a 99.93% decline year-over-year.
- MANNKIND CORP foreign currency transaction gain (loss), realized for the quarter ending 2025-09-30 was $120.00K.
- MANNKIND CORP foreign currency transaction gain (loss), realized for fiscal 2025 was -$7.75M, a 298.34% decline from fiscal 2024.
- MANNKIND CORP foreign currency transaction gain (loss), realized for fiscal 2024 was $3.91M.
- MANNKIND CORP foreign currency transaction gain (loss), realized for fiscal 2023 was -$1.92M, a 139.83% decline from fiscal 2022.
- MANNKIND CORP foreign currency transaction gain (loss), realized for fiscal 2022 was $4.81M, a 26.74% decline from fiscal 2021.
| Period end | Foreign Currency Transaction Gain (Loss), Realized 3 month | Foreign Currency Transaction Gain (Loss), Realized 6 month | Foreign Currency Transaction Gain (Loss), Realized 9 month | Foreign Currency Transaction Gain (Loss), Realized 12 month |
|---|---|---|---|---|
| 2026-06-30 | $486.00K 10-Q · filed 2026-08-05 | $1.80M 10-Q · filed 2026-08-05 | $1.81M derived: sum of 3 quarters · filed 2026-08-05 | $1.93M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $1.32M 10-Q · filed 2026-05-06 | $1.32M derived: sum of 2 quarters · filed 2026-05-06 | $1.44M derived: sum of 3 quarters · filed 2026-05-06 | -$3.92M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $123.00K derived: sum of 2 quarters · filed 2026-02-26 | -$5.24M derived: sum of 3 quarters · filed 2026-08-05 | -$7.75M 10-K · filed 2026-02-26 |
| 2025-09-30 | $120.00K 10-Q · filed 2025-11-05 | -$5.24M derived: sum of 2 quarters · filed 2026-08-05 | -$7.75M 10-Q · filed 2025-11-05 | -$3.32M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$5.36M 10-Q · filed 2026-08-05 | -$7.87M 10-Q · filed 2026-08-05 | -$3.44M derived: sum of 3 quarters · filed 2026-08-05 | -$5.89M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$2.51M 10-Q · filed 2026-05-06 | $1.92M derived: sum of 2 quarters · filed 2026-05-06 | -$530.00K derived: sum of 3 quarters · filed 2026-05-06 | -$1.00K derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $4.43M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.98M derived: sum of 2 quarters · filed 2026-02-26 | $2.51M derived: sum of 3 quarters · filed 2026-02-26 | $3.91M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$2.45M 10-Q · filed 2025-11-05 | -$1.93M derived: sum of 2 quarters · filed 2025-11-05 | -$526.00K 10-Q · filed 2025-11-05 | -$3.30M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $529.00K 10-Q · filed 2025-08-06 | $1.93M 10-Q · filed 2025-08-06 | -$848.00K derived: sum of 3 quarters · filed 2026-02-26 | $1.22M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $1.40M 10-Q · filed 2025-05-08 | -$1.38M derived: sum of 2 quarters · filed 2026-02-26 | $688.00K derived: sum of 3 quarters · filed 2026-02-26 | $437.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$2.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$711.00K derived: sum of 2 quarters · filed 2026-02-26 | -$962.00K derived: sum of 3 quarters · filed 2026-02-26 | -$1.92M 10-K · filed 2026-02-26 |
| 2023-09-30 | $2.06M 10-Q · filed 2024-11-07 | $1.81M derived: sum of 2 quarters · filed 2024-11-07 | $860.00K 10-Q · filed 2024-11-07 | -$2.61M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | -$251.00K 10-Q · filed 2024-08-07 | -$1.21M 10-Q · filed 2024-08-07 | -$4.68M derived: sum of 3 quarters · filed 2025-02-26 | -$2.88M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | -$954.00K 10-Q · filed 2024-05-08 | -$4.43M derived: sum of 2 quarters · filed 2025-02-26 | -$2.63M derived: sum of 3 quarters · filed 2025-02-26 | $1.87M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | -$3.47M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | -$1.68M derived: sum of 2 quarters · filed 2025-02-26 | $2.83M derived: sum of 3 quarters · filed 2025-02-26 | $4.81M 10-K · filed 2025-02-26 |
| 2022-09-30 | $1.80M 10-Q · filed 2023-11-07 | $6.30M derived: sum of 2 quarters · filed 2023-11-07 | $8.29M 10-Q · filed 2023-11-07 | $9.85M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $4.50M 10-Q · filed 2023-08-07 | $6.49M 10-Q · filed 2023-08-07 | $8.05M derived: sum of 3 quarters · filed 2024-02-27 | $10.12M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $1.98M 10-Q · filed 2023-05-09 | $3.55M derived: sum of 2 quarters · filed 2024-02-27 | $5.62M derived: sum of 3 quarters · filed 2024-02-27 | $4.71M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $1.56M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $3.63M derived: sum of 2 quarters · filed 2024-02-27 | $2.73M derived: sum of 3 quarters · filed 2024-02-27 | $6.57M 10-K · filed 2024-02-27 |
| 2021-09-30 | $2.07M 10-Q · filed 2022-11-08 | $1.17M derived: sum of 2 quarters · filed 2022-11-08 | $5.00M 10-Q · filed 2022-11-08 | $995.00K derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | -$903.00K 10-Q · filed 2022-08-09 | $2.94M 10-Q · filed 2022-08-09 | -$1.07M derived: sum of 3 quarters · filed 2023-02-23 | -$5.00M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $3.84M 10-Q · filed 2022-05-05 | -$170.00K derived: sum of 2 quarters · filed 2023-02-23 | -$4.10M derived: sum of 3 quarters · filed 2023-02-23 | -$5.96M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | -$4.01M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$7.93M derived: sum of 2 quarters · filed 2023-02-23 | -$9.80M derived: sum of 3 quarters · filed 2023-02-23 | -$8.01M 10-K · filed 2023-02-23 |
| 2020-09-30 | -$3.93M 10-Q · filed 2021-11-09 | -$5.79M derived: sum of 2 quarters · filed 2021-11-09 | -$4.00M 10-Q · filed 2021-11-09 | -$6.58M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | -$1.87M 10-Q · filed 2021-08-11 | -$71.00K 10-Q · filed 2021-08-11 | -$2.65M derived: sum of 3 quarters · filed 2021-08-11 | $1.15M derived: sum of 4 quarters · filed 2021-08-11 |
| 2020-03-31 | $1.80M 10-Q · filed 2021-05-12 | -$786.00K derived: sum of 2 quarters · filed 2021-05-12 | $3.02M derived: sum of 3 quarters · filed 2021-05-12 | $1.77M derived: sum of 4 quarters · filed 2021-05-12 |
| 2019-12-31 | -$2.58M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $1.23M derived: sum of 2 quarters · filed 2021-02-25 | -$22.00K derived: sum of 3 quarters · filed 2021-02-25 | $1.91M 10-K · filed 2021-02-25 |
| 2019-09-30 | $3.81M 10-Q · filed 2020-11-04 | $2.56M derived: sum of 2 quarters · filed 2020-11-04 | $4.50M 10-Q · filed 2020-11-04 | $5.86M derived: sum of 4 quarters · filed 2020-11-04 |
| 2019-06-30 | -$1.25M 10-Q · filed 2020-08-05 | $688.00K 10-Q · filed 2020-08-05 | $2.05M derived: sum of 3 quarters · filed 2020-08-05 | $2.78M derived: sum of 4 quarters · filed 2020-08-05 |
| 2019-03-31 | $1.94M 10-Q · filed 2020-05-06 | $3.30M derived: sum of 2 quarters · filed 2020-05-06 | $4.02M derived: sum of 3 quarters · filed 2020-05-06 | $9.39M derived: sum of 4 quarters · filed 2020-05-06 |
| 2018-12-31 | $1.36M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $2.09M derived: sum of 2 quarters · filed 2020-02-25 | $7.45M derived: sum of 3 quarters · filed 2020-02-25 | $4.47M 10-K · filed 2020-02-25 |
| 2018-09-30 | $728.00K 10-Q · filed 2019-11-08 | $6.09M derived: sum of 2 quarters · filed 2019-11-08 | $3.11M 10-Q · filed 2019-11-08 | $1.54M derived: sum of 4 quarters · filed 2019-11-08 |
| 2018-06-30 | $5.36M 10-Q · filed 2019-08-07 | $2.38M 10-Q · filed 2019-08-07 | $815.00K derived: sum of 3 quarters · filed 2019-08-07 | -$2.87M derived: sum of 4 quarters · filed 2019-08-07 |
| 2018-03-31 | -$2.98M 10-Q · filed 2019-05-07 | -$4.55M derived: sum of 2 quarters · filed 2019-05-07 | -$8.23M derived: sum of 3 quarters · filed 2019-05-07 | -$15.08M derived: sum of 4 quarters · filed 2019-05-07 |
| 2017-12-31 | -$1.56M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | -$5.25M derived: sum of 2 quarters · filed 2019-02-26 | -$12.10M derived: sum of 3 quarters · filed 2019-02-26 | -$13.64M 10-K · filed 2019-02-26 |
| 2017-09-30 | -$3.68M 10-Q · filed 2018-11-01 | -$10.53M derived: sum of 2 quarters · filed 2018-11-01 | -$12.08M 10-Q · filed 2018-11-01 | -$5.61M derived: sum of 4 quarters · filed 2019-02-26 |
| 2017-06-30 | -$6.85M 10-Q · filed 2018-08-02 | -$8.39M 10-Q · filed 2018-08-02 | -$1.93M derived: sum of 3 quarters · filed 2019-02-26 | -$2.94M derived: sum of 4 quarters · filed 2019-02-26 |
| 2017-03-31 | -$1.54M 10-Q · filed 2018-05-09 | $4.92M derived: sum of 2 quarters · filed 2019-02-26 | $3.91M derived: sum of 3 quarters · filed 2019-02-26 | $4.25M derived: sum of 4 quarters · filed 2019-02-26 |
| 2016-12-31 | $6.47M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $5.46M derived: sum of 2 quarters · filed 2019-02-26 | $5.80M derived: sum of 3 quarters · filed 2019-02-26 | $3.43M 10-K · filed 2019-02-26 |
| 2016-09-30 | -$1.01M 10-Q · filed 2017-11-07 | -$671.00K derived: sum of 2 quarters · filed 2017-11-07 | -$3.04M 10-Q · filed 2017-11-07 | |
| 2016-06-30 | $341.00K 10-Q · filed 2017-08-07 | -$2.02M 10-Q · filed 2017-08-07 | ||
| 2016-03-31 | -$2.36M 10-Q · filed 2017-05-10 | |||
| 2015-12-31 | -$2.70M 10-K · filed 2018-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |